Adelaide, South Australia (June 20, 2017) – Innokeys Pte Ltd attended ANZCHOG 2017 – a conference which is organized annually by the Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG). Dr Normando Iznaga-Escobar, the Scientific Officer of Innokeys Pte Ltd, attended ANZCHOG 2017 to present a poster summarizing 10 years of experience with the use of nimotuzumab, an anti-EGFR humanized monoclonal antibody, for the treatment of newly diagnosed children with Diffuse Intrinsic Pontine Glioma (DIPG) and in recurrent or refractory children with high grade glioma. The poster summarised the results of 112 newly diagnosed children with DIPG recruited into 2 clinical studies and 1 physician led study as well as 128 children with recurrent or refractory high-grade glioma recruited into 2 clinical studies and 2 physician lead studies. In conclusion, the 10-year use of nimotuzumab used in combination with radiotherapy and radio chemotherapy was seen to be efficacious in children newly diagnosed with DIPG and recurrent or refractory high-grade glioma. Click here to view the poster About the Event ANZCHOG is an annual conference held in either Australia or New Zealand organized by a multidisciplinary, cooperative group of professionals working in the fields of paediatric blood diseases and cancer. The organization was formed to provide a foundation for collaboration to among others, engage in quality research and paediatric cancer clinical trials to ensure that all children and adolescents with cancer and associated blood diseases are provided with the highest quality, evidence-based care to ensure optimal outcomes in terms of survivorship and quality of life. The ANZCHOG 2017 conference took place between the 15th – 17th of June at the Hilton hotel in Adelaide.